Sep 03, 2020 10:30am EDT JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials
Aug 28, 2020 2:34pm EDT JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials
Aug 26, 2020 9:45am EDT JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness
Aug 21, 2020 10:31am EDT JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
Aug 11, 2020 6:00pm EDT Correction -- JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials
Aug 11, 2020 9:37am EDT JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials
Aug 06, 2020 2:30pm EDT JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
Jul 30, 2020 9:30am EDT JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain
